Showing 3791-3800 of 6035 results for "".
- OD-OS to Showcase Navilas Navigated Retinal Laser Therapy at EURETINAhttps://modernod.com/news/od-os-to-showcase-navilas-navigated-retinal-laser-therapy-at-euretina/2476852/OD-OS will share clinical experiences with the Navilas 577s digital treatment platform this week at the EURETINA Congress in Paris. Navigated retinal laser therapy with the Navilas 577s allows for panretinal photocoagulation with uniform spot distribution, which is faster and less painful for pat
- Oculus Release Myopia Master for Myopia Managementhttps://modernod.com/news/oculus-release-myopia-master-for-myopia-management/2476839/Oculus has introduced the Myopia Master, a device designed to combine all the important measurement methods of myopia management: axial length, refraction values, and the central corneal radii. The Oculus Myopia Master creates a myopia report for each patient, giving due consideration to s
- OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113 in a Mouse Model of Dry Eye Diseasehttps://modernod.com/news/okyo-pharma-announces-potent-anti-inflammatory-effects-of-ok-113-in-a-mouse-model-of-dry-eye-disease/2476830/OKYO Pharma has announced potent anti-inflammatory activity of OK-113, an in-house discovered proprietary agonist of Chemerin GPCR, in an experimental model of dry eye disease (DED) in mice. These preclinical efficacy data, identifying a lead drug candidate, will facilitate initiation of clinical
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval/2476825/Staar Surgical announced that the FDA, in a letter dated August 23, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ Visian Implantable Collamer Lens for myopia, and EVO/EVO+ Visian Tor
- Oculus Introduces Pentacam AXL Wavehttps://modernod.com/news/oculus-introduces-pentacam-axl-wave/2479548/Oculus has announced that it plans to introduce its next-generation Pentacam—the Pentacam AXL Wave. The new Pentacam AXL Wave is the first device to combine Scheimpflug tomography with axial length, total eye wavefront, objective refraction, and retroillumination, according to Oculus. New
- Bausch Health CEO: Big Pharma Will Survive US Drug Regulationshttps://modernod.com/news/bausch-health-ceo-big-pharma-will-survive-us-drug-regulations/2476798/Bausch Health Chariman and CEO Joseph C. Papa told CNBC on Wednesday that he isn’t too concerned about the future of the pharmaceutical industry despite pledges from Congress to lower
- Glaukos Announces Agreement to Buy Avedro in All-Stock Dealhttps://modernod.com/news/glaukos-announces-agreement-to-buy-avedro-in-all-stock-deal/2479551/In a move to diversify its offerings and expand its corneal health franchise, Glaukos agreed to acquire cross-linking company Avedro in an all-stock transaction.
- Rare Complication of Eye Surgery Can Kill in a Minutehttps://modernod.com/news/rare-complication-of-eye-surgery-can-kill-in-a-minute/2476790/Ocular venous air embolism, a very rare complication of vitrectomy, is almost always fatal, yet some retina specialists have not heard of it, according to a Medscape report. The complication can kill in less than a minute, said Rob
- Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Anti-Microbial Ophthalmic and Otic Therapeuticshttps://modernod.com/news/harrow-health-forms-stowe-pharmaceuticals-subsidiary-to-develop-anti-microbial-ophthalmic-and-otic-therapeutics/2479553/Harrow Health announced that its newly formed subsidiary, Stowe Pharmaceuticals, has entered into an agreement with TGV Health to acquire worldwide rights to the Zian anti-microbial molecule for ophthalmic and otic uses. Zian is a patented small molecule that is water soluble, colorless,
- Staar Surgical Announces Submission of Presbyopia Clinical Trial Datahttps://modernod.com/news/staar-surgical-announces-submission-of-presbyopia-clinical-trial-data/2479554/Staar Surgical announced the submission of its multisite European pivotal clinical trial data for the EVO+ Visian ICL with Aspheric (EDOF) Optic, a lens that is designed to provide correction or reduction of myopia or hyperopia and presbyopia. Results from the clinical trial were submitted to DEK